Display options
Cite
Henrich TJ, McLaren PJ, Rao SS, et al. Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis. 2014;1(1):ofu018doi: 10.1093/ofid/ofu018.
Henrich, T. J., McLaren, P. J., Rao, S. S., Lin, N. H., Hanhauser, E., Giguel, F., Gulick, R. M., Ribaudo, H., de Bakker, P. I., & Kuritzkes, D. R. (2014). Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open forum infectious diseases, 1(1), ofu018. https://doi.org/10.1093/ofid/ofu018
Henrich, Timothy J, et al. "Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study." Open forum infectious diseases vol. 1,1 (2014): ofu018. doi: https://doi.org/10.1093/ofid/ofu018
Henrich TJ, McLaren PJ, Rao SS, Lin NH, Hanhauser E, Giguel F, Gulick RM, Ribaudo H, de Bakker PI, Kuritzkes DR. Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study. Open Forum Infect Dis. 2014 May 22;1(1):ofu018. doi: 10.1093/ofid/ofu018. eCollection 2014 Mar. PMID: 25734091; PMCID: PMC4324186.
Copy Download .nbib Format: NLM
Share it on

Open Forum Infect Dis. 2014 May 22;1(1):ofu018. doi: 10.1093/ofid/ofu018. eCollection 2014 Mar.

Genome-Wide Association Study of Human Immunodeficiency Virus (HIV)-1 Coreceptor Usage in Treatment-Naive Patients from An AIDS Clinical Trials Group Study.

Open forum infectious diseases

Timothy J Henrich, Paul J McLaren, Suhas S P Rao, Nina H Lin, Emily Hanhauser, Francoise Giguel, Roy M Gulick, Heather Ribaudo, Paul I W de Bakker, Daniel R Kuritzkes

Affiliations

  1. Division of Infectious Diseases , Brigham and Women's Hospital , Boston, Massachusetts ; Harvard Medical School , Boston, Massachusetts.
  2. École Polytechnique Fédérale de Lausanne and University of Lausanne , Switzerland ; University Hospital and University of Lausanne , Switzerland ; Swiss Institute of Bioinformatics , Switzerland.
  3. Harvard University, Cambridge, Massachusetts.
  4. Massachusetts General Hospital , Boston, Massachusetts ; Harvard Medical School , Boston, Massachusetts.
  5. Division of Infectious Diseases , Brigham and Women's Hospital , Boston, Massachusetts.
  6. Massachusetts General Hospital , Boston, Massachusetts.
  7. Weill Medical College of Cornell University, New York, New York.
  8. Harvard Medical School , Boston, Massachusetts ; Harvard School of Public Health.
  9. Harvard Medical School , Boston, Massachusetts ; Program in Medical and Population Genetics , Broad Institute of Harvard and MIT , Boston, Massachusetts ; Department of Medical Genetics and Department of Epidemiology , University Medical Center Utrecht , Utrecht , The Netherlands ; Divison of Genetics , Brigham and Women's Hospital , Boston, Massachusetts.

PMID: 25734091 PMCID: PMC4324186 DOI: 10.1093/ofid/ofu018

Abstract

OBJECTIVES: We conducted a genome-wide association study to explore whether common host genetic variants (>5% frequency) were associated with presence of virus able to use CXCR4 for entry.

METHODS: Phenotypic determination of human immunodeficiency virus (HIV)-1 coreceptor usage was performed on pretreatment plasma HIV-1 samples from treatment-naive participants in AIDS Clinical Trials Group A5095, a study of initial antiretroviral regimens. Associations between genome-wide single-nucleotide polymorphisms (SNPs), CCR5 Δ32 genotype, and human leukocyte antigen (HLA) class I alleles and viral coreceptor usage were explored.

RESULTS: Viral phenotypes were obtained from 593 patients with available genome-wide SNP data. Forty-four percent of subjects had virus capable of using CXCR4 for entry as determined by phenotyping. Overall, no associations, including those between polymorphisms in genes encoding viral coreceptors and their promoter regions or in HLA genes previously associated with HIV-1 disease progression, passed the statistical threshold for genome-wide significance (P < 5.0 × 10(-8)) in any comparison. However, the presence of viruses able to use CXCR4 for entry was marginally associated with the CCR5 Δ32 genotype in the nongenome-wide analysis.

CONCLUSIONS: No human genetic variants were significantly associated with virus able to use CXCR4 for entry at the genome-wide level. Although the sample size had limited power to definitively exclude genetic associations, these results suggest that host genetic factors, including those that influence coreceptor expression or the immune pressures leading to viral envelope diversity, are either rare or have only modest effects in determining HIV-1 coreceptor usage.

Keywords: CCR5 Δ32 mutation; HIV-1; genome-wide association study; viral coreceptor usage; viral tropism

References

  1. J Virol. 2012 Jan;86(2):1119-28 - PubMed
  2. Nat Immunol. 2007 Dec;8(12):1324-36 - PubMed
  3. N Engl J Med. 2014 Mar 6;370(10):901-10 - PubMed
  4. AIDS. 2010 Sep 10;24(14):2181-6 - PubMed
  5. N Engl J Med. 2004 Apr 29;350(18):1850-61 - PubMed
  6. Curr Opin HIV AIDS. 2009 Mar;4(2):125-30 - PubMed
  7. Nature. 2012 Nov 1;491(7422):56-65 - PubMed
  8. Nature. 1996 Aug 22;382(6593):722-5 - PubMed
  9. Nature. 1996 Aug 29;382(6594):833-5 - PubMed
  10. J Exp Med. 2004 Sep 20;200(6):761-70 - PubMed
  11. Science. 1998 Dec 4;282(5395):1907-11 - PubMed
  12. J Infect Dis. 2005 Aug 1;192(3):466-74 - PubMed
  13. Nat Biotechnol. 2010 Aug;28(8):839-47 - PubMed
  14. J Virol. 2000 Jun;74(12):5452-9 - PubMed
  15. Nat Biotechnol. 2007 Dec;25(12):1407-10 - PubMed
  16. Clin Infect Dis. 2007 Sep 1;45(5):643-9 - PubMed
  17. Curr Opin HIV AIDS. 2011 Jan;6(1):74-9 - PubMed
  18. Ann Intern Med. 1993 May 1;118(9):681-8 - PubMed
  19. Nat Med. 2008 Apr;14(4):413-20 - PubMed
  20. J Virol Methods. 2010 Oct;169(1):39-46 - PubMed
  21. J Infect Dis. 2008 Jan 15;197(2):309-18 - PubMed
  22. J Virol. 1999 Dec;73(12):10489-502 - PubMed
  23. J Acquir Immune Defic Syndr. 2005 Apr 1;38(4):382-92 - PubMed
  24. Blood. 2011 Feb 10;117(6):2073-4 - PubMed
  25. N Engl J Med. 2009 Feb 12;360(7):692-8 - PubMed
  26. Science. 1997 Aug 15;277(5328):959-65 - PubMed
  27. Virology. 2009 Nov 10;394(1):64-72 - PubMed
  28. Science. 2010 Dec 10;330(6010):1551-7 - PubMed
  29. J Virol. 2009 Oct;83(19):9694-708 - PubMed
  30. J Virol Methods. 2007 Jul;143(1):104-11 - PubMed
  31. J Exp Med. 1997 Feb 17;185(4):621-8 - PubMed
  32. J Infect Dis. 2005 Nov 1;192(9):1597-605 - PubMed
  33. J Virol. 2006 Jan;80(2):802-9 - PubMed
  34. J Acquir Immune Defic Syndr. 2010 Dec;55(4):420-7 - PubMed
  35. Am J Hum Genet. 2007 Sep;81(3):559-75 - PubMed
  36. Retrovirology. 2008 Jan 18;5:5 - PubMed
  37. Science. 2007 Aug 17;317(5840):944-7 - PubMed
  38. Virology. 2008 Sep 15;379(1):125-34 - PubMed
  39. J Virol. 1992 Mar;66(3):1354-60 - PubMed
  40. Proc Natl Acad Sci U S A. 2000 Mar 14;97(6):2709-14 - PubMed
  41. HIV Clin Trials. 2003 Sep-Oct;4(5):287-300 - PubMed
  42. Clin Infect Dis. 2007 Feb 15;44(4):591-5 - PubMed
  43. Proc Natl Acad Sci U S A. 1999 Oct 12;96(21):12004-9 - PubMed
  44. AIDS Res Hum Retroviruses. 2004 Jan;20(1):111-26 - PubMed
  45. J Infect Dis. 1994 May;169(5):968-74 - PubMed

Publication Types

Grant support